医学
米拉贝格伦
荟萃分析
支架
坦索罗辛
随机对照试验
不利影响
安慰剂
内科学
膀胱过度活动
替代医学
病理
增生
作者
Zhouyue Li,Yuanshan Cui,Yumeng Chai,Yong Zhang
摘要
This meta-analysis aimed to assess the efficacy and safety of mirabegron in treating ureteral stent-related symptoms.MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched to identify randomized controlled trials (RCT) of mirabegron in treating ureteral stent-related symptoms. We conducted a systematic review and meta-analysis based on the eligible RCT.Five RCT including 546 patients and comparing mirabegron with placebo or blank control were involved in the present research. Regarding efficacy, mirabegron was superior to controls in urinary symptom score (P = .0006) and general health score (P < .0001) of the Ureteral Stent Symptom Questionnaire, total International Prostate Symptom Score (P < .00001), quality of life (P < .0001), analgesic use (P = .008), and readmission or visit to hospital due to discomfort (P = .001). Safety assessments including adverse events (P = .40) suggested that mirabegron was well tolerated.The present meta-analysis shows that mirabegron is an effective and safe treatment for relieving ureteral stent-related symptoms with a low occurrence of adverse events.
科研通智能强力驱动
Strongly Powered by AbleSci AI